{"id":"NCT02692703","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","officialTitle":"A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-22","primaryCompletion":"2017-04-13","completion":"2017-06-29","firstPosted":"2016-02-26","resultsPosted":"2018-04-04","lastUpdate":"2021-07-13"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C","HCV","Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"glecaprevir/pibrentasvir","otherNames":["glecaprevir also known as ABT-493","pibrentasvir also known as ABT-530","MAVYRET"]}],"arms":[{"label":"Glecaprevir/Pibrentasvir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last dose of study drug (up to 24 weeks)","effectByArm":[{"arm":"Glecaprevir/Pibrentasvir","deltaMin":98,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29672891"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":100},"commonTop":["Fatigue","Headache","Nausea","Pruritus","Diarrhoea"]}}